Iovance Biotherapeutics, Inc.

This study tests a treatment made from your own immune cells (called TIL or LN-145) to see if it can shrink tumors in people with advanced non-small-cell lung cancer that has spread. About 170 adults with stage IV lung cancer will receive their own specially grown immune cells. T…

This program offers AMTAGVI, a cell therapy, to people with advanced melanoma that cannot be removed by surgery or has spread. It is for patients whose manufactured dose did not meet commercial standards but was still considered safe. The goal is to provide treatment access when …

This study tests a treatment called lifileucel, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced endometrial cancer. About 60 people who have already tried other treatments will receive this cell therapy. The main goal is to see if the tr…

This early-phase study tests a new drug (IOV-3001) designed to boost immune cells in people with advanced melanoma that has not responded to prior treatments. About 42 adults will receive the drug alongside a personalized cell therapy called lifileucel. The main goals are to chec…

This study tests whether adding a personalized immune cell therapy (lifileucel) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma that has not been treated yet. About 670 participants will receive either the combinat…